{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:34:55Z","timestamp":1792146895930,"version":"4.4.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent attempts to define and classify patients with marked eosinophilia and features consistent with myeloproliferative disease, areas of controversy remain. These are particularly apparent in situations in which multiple lineages are involved in a clonal process and clinical manifestations are overlapping. Although the introduction of new molecular diagnostics and targeted therapies has begun to clarify the boundaries between some of these disorders, several questions remain with respect to the classification of patients with myeloproliferative hypereosinophilic syndrome (HES) of unknown etiology.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.257","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Eosinophilic Myeloproliferative Disorders"],"prefix":"10.1182","volume":"2011","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716205722400_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine"},{"key":"2019111716205722400_B2","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue","author":"Jaffe","year":"2001","edition":"3rd ed"},{"key":"2019111716205722400_B3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"2019111716205722400_B4","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Redefining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B7","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"2019111716205722400_B8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood.V58.5.1012.bloodjournal5851012","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations","volume":"58","author":"Flaum","year":"1981","journal-title":"Blood"},{"key":"2019111716205722400_B9","first-page":"253","article-title":"Prognostic factors of hypereosinophilic syndrome. Study of 40 cases [Article in French]","volume":"140","author":"Lefebvre","year":"1989","journal-title":"Ann Med Interne (Paris)"},{"key":"2019111716205722400_B10","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib-responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"2019111716205722400_B11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","article-title":"Molecular characterization of the idiopathic hypereosiophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics","volume":"19","author":"Roche-Lestienne","year":"2005","journal-title":"Leukemia"},{"key":"2019111716205722400_B12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRA alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"2019111716205722400_B13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716205722400_B14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukemia and hypereosinophilic syndrome\u2013a phase II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111716205722400_B15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2008.309","article-title":"Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions","volume":"23","author":"Score","year":"2009","journal-title":"Leukemia"},{"key":"2019111716205722400_B17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/gcc.20359","article-title":"Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene","volume":"45","author":"Walz","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111716205722400_B18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","article-title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukemia","volume":"138","author":"Curtis","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B19","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling","year":"2011","journal-title":"Blood"},{"key":"2019111716205722400_B20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/pbc.22655","article-title":"Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate","volume":"55","author":"Rathe","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2019111716205722400_B21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1\/PDGFRA(+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"2019111716205722400_B22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2133.2006.07416.x","article-title":"Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis","volume":"155","author":"McPherson","year":"2006","journal-title":"Br J Dermatol"},{"key":"2019111716205722400_B23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1468-3083.2009.03382.x","article-title":"Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP-like 1-platelet-derived growth factor receptor alpha fusion gene","volume":"24","author":"Thuny","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2019111716205722400_B24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaci.2003.10.051","article-title":"Hypereosinophilic syndrome: case presentation and update","volume":"113","author":"Leiferman","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428194.2010.534210","article-title":"Concomitant FIP1L1-PDFGRA fusion gene and T cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and and incomplete repsonse to imatinib","volume":"52","author":"Burbury","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2019111716205722400_B27","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities ar epresent at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica"},{"key":"2019111716205722400_B28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0609.2007.00973.x","article-title":"Synchronous FIP1L1-PDGFRA-positive chronic eosinohpilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy","volume":"80","author":"Capovilla","year":"2008","journal-title":"Eur J Haematol"},{"key":"2019111716205722400_B29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remisison of chronic eosinophilic leukemia in FIP1L1\/PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B31","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"key":"2019111716205722400_B32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1080\/10428190400005288","article-title":"Imatinib-repsonsive hypereosinophilia in a patient with B cell ALL","volume":"45","author":"Robyn","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2019111716205722400_B33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"2019111716205722400_B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"2019111716205722400_B35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13b","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Gambacorti-Passerini","year":"2007","journal-title":"Nat Med"},{"key":"2019111716205722400_B36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"key":"2019111716205722400_B37","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia:implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"2019111716205722400_B38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","article-title":"Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B39","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"2019111716205722400_B40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"2019111716205722400_B41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","article-title":"Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from langerhans cell histiocytosis with eosinophilia after chemotherapy","volume":"134","author":"Ohnishi","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"2019111716205722400_B43","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.leukres.2010.02.024","article-title":"Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib","volume":"34","author":"Ikezoe","year":"2010","journal-title":"Leuk Res"},{"key":"2019111716205722400_B44","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro","volume":"30","author":"von Bubnoff","year":"2011","journal-title":"Oncogene"},{"key":"2019111716205722400_B45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","author":"Ueno","year":"2002","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-4608(98)00099-5","article-title":"Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review and report of a case with a unique chromosomal abnormality","volume":"107","author":"Oliver","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111716205722400_B47","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"key":"2019111716205722400_B48","first-page":"651","article-title":"AlphaIFN-induced hematologic and cytogeentic remission in chronic eosinophilia leukemia with t(1;5)","volume":"84","author":"Luciano","year":"1999","journal-title":"Haematologica"},{"key":"2019111716205722400_B49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.1996.00298.x","article-title":"Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematologic and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality","volume":"92","author":"Malbrain","year":"1996","journal-title":"Br J Haematol"},{"key":"2019111716205722400_B50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000046640","article-title":"Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report","volume":"107","author":"Granjo","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111716205722400_B51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"2019111716205722400_B52","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"2019111716205722400_B53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"2019111716205722400_B54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111716205722400_B55","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"2019111716205722400_B56","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0046-8177(85)80252-5","article-title":"Bone marrow findings in systemic mastocytosis","volume":"16","author":"Horny","year":"1985","journal-title":"Human Pathol"},{"key":"2019111716205722400_B57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2019111716205722400_B58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systmeic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"2019111716205722400_B59","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The KIT mutation causing human mastocytosis is rresistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"2019111716205722400_B60","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"2019111716205722400_B61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A case of mast cell leukaemia with exon 9 KIT mutation and good repsonse to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"Eur J Haematol"},{"key":"2019111716205722400_B62","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid disease, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019111716205722400_B63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/257\/1495217\/bep00111000257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/257\/1495217\/bep00111000257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:24:07Z","timestamp":1713187447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/257\/96956\/Eosinophilic-Myeloproliferative-Disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.257","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}